Cytosorbents

CTSO NASDAQ
7.10
+0.07
+1.00%
Opening 14:56 07/15 EDT
Open
7.05
Prev Close
7.03
High
7.11
Low
6.86
Volume
71.44K
Avg Vol (3M)
116.30K
52 Week High
14.95
52 Week Low
5.84
% Turnover
0.22%
Market Cap
228.97M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Cytosorbents CTSO stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
MORE >

Recently

Name
Price
%Change